Modified GIP Peptides Proteolysis Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current GIP analogues have a short in vivo half-life due to susceptibility to proteolysis, leading to instability and reduced efficacy as therapeutic agents for conditions like non-insulin dependent diabetes mellitus and obesity, as they are degraded by dipeptidyl peptidase IV, resulting in fragments that act as receptor antagonists.
Innovation Solution
Development of peptide variants of GIP with specific modifications such as A6c, Cys(Psu), and PEGylation to enhance stability, reduce clearance, and maintain binding affinity to the GIP receptor, thereby prolonging plasma half-life and improving therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If unmodified GIP is used as a therapeutic agent, then it can bind to GIP receptors and exert physiological effects, but it has a short in vivo half-life due to rapid degradation by dipeptidyl peptidase IV
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence of GIP at specific positions (N-terminal tyrosine, alanine at position 2, glutamic acid at position 3, and alanine at position 13) to alter its resistance to proteolytic degradation. These sequence modifications change the chemical parameters of the peptide while preserving its ability to bind to GIP receptors, thereby extending its in vivo half-life from approximately 2 minutes to significantly longer durations.
Solution Approach 2:
The patent employs composite materials by combining modified GIP peptide sequences with protective chemical structures, such as N-terminal acetylation or alternative amino acid substitutions. This creates a composite therapeutic molecule that integrates both the bioactive GIP region and protective elements that shield against DPPIV degradation, achieving both receptor affinity and extended stability.
2Reliability
If GIP is degraded by dipeptidyl peptidase IV, then it loses its agonist activity, but degradation produces fragments that act as GIP receptor antagonists
Solution Approach 1:
The patent applies preliminary anti-action by pre-modifying the GIP molecule with protective chemical groups or amino acid substitutions at cleavage sites before administration. This preliminary protection prevents the harmful degradation process from occurring in vivo, thereby maintaining agonist activity and preventing the formation of antagonist fragments that would otherwise be generated by DPPIV cleavage.
Solution Approach 2:
The patent converts the harmful effect of proteolytic degradation into a benefit by designing modifications that specifically block cleavage at DPPIV sites. The modifications are positioned to prevent degradation without affecting receptor binding, thereby transforming what would be a harmful degradation pathway into a stable, long-acting therapeutic agent that maintains consistent agonist activity.
3Duration of action of moving object
If the in vivo half-life of GIP is extended through modifications, then therapeutic efficacy is improved, but the complexity of the molecule increases
Solution Approach 1:
The patent applies local quality by making targeted modifications at specific local positions within the GIP molecule (N-terminal region and positions 2, 3, and 13) rather than throughout the entire sequence. These localized changes provide the necessary protection and extended half-life while minimizing overall molecular complexity and maintaining the majority of the native GIP structure for optimal receptor interaction.
Solution Approach 2:
The patent employs partial action by implementing modifications at only the critical cleavage sites identified for DPPIV degradation, rather than protecting the entire molecule uniformly. This selective approach achieves sufficient half-life extension with minimal structural complexity, applying protection only where most needed to prevent degradation and maintain therapeutic efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified GIP analogues exhibit increased stability and prolonged action, providing tighter control of plasma glucose levels and improved therapeutic outcomes for diabetes-related conditions, including enhanced insulin secretion and weight management.
Implementation Method 1
In serum, both incretins, GIP and GLP-1, are degraded by dipeptidyl peptidase IV ('DPPIV'). Improving the stability of GIP to proteolysis not only maintains the activity of GIP at its receptor but, more importantly, prevents the production of GIP fragments
Implementation Method 2
Development of peptide variants of GIP with specific modifications such as A6c, Cys(Psu), and PEGylation to enhance stability, reduce clearance, and maintain binding affinity to the GIP receptor, thereby prolonging plasma half-life
Data Source
AI summary
There is provided a novel series of analogues of glucose-dependent insulinotropic polypeptide, pharmaceutical compositions containing said compounds, and the use of said compounds as GIP- receptor agonists or antagonists for treatment of GIP-receptor mediated conditions, such as non- insulin dependent diabetes mellitus and obesity.